PPL
54
-5
DHI
48
4
NKE
36
6
AMG
54
2
PRGO
39
3
CFG
70
6
CSX
60
3
ES
34
3
LH
43
-2
INTU
56
-4
WY
54
4
HON
67
2
DTE
56
2
ORCL
65
-2
FITB
63
3
NDAQ
62
2
IR
66
3
STZ
54
-3
SYK
64
-4
BSX
67
-3
PPL
54
-5
DHI
48
4
NKE
36
6
AMG
54
2
PRGO
39
3
CFG
70
6
CSX
60
3
ES
34
3
LH
43
-2
INTU
56
-4
WY
54
4
HON
67
2
DTE
56
2
ORCL
65
-2
FITB
63
3
NDAQ
62
2
IR
66
3
STZ
54
-3
SYK
64
-4
BSX
67
-3
Financhill
Back

CASI Pharmaceuticals 10K Form

Sell
48

CASI
CASI Pharmaceuticals

Last Price:
5.11
Seasonality Move:
9.59%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CASI News And Ratings

See the #1 stock for the next 7 days that we like better than CASI

CASI Financial Statistics

Sales & Book Value

Annual Sales: $33.88M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $0.90
Price / Book: 5.69

Profitability

EPS (TTM): -2.24000
Net Income (TTM): $-30.94M
Gross Margin: $20.05M
Return on Equity: -137%
Return on Assets: -47.99%

CASI Pharmaceuticals Earnings Forecast

Key CASI Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 28 years for CASI is 59.19%.
  • The Selling, General & Administrative Expenses for CASI have been equal to 123.49% of Gross Profit Margin.
  • The Research & Development expenses have been 29.11% of Revenue.
  • The Interest Expense is 2.30% of Operating Income.
  • The Net Earning history of CASI is -79.51% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 15 years.

CASI Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CASI
CUSIP: 14757U
Website: casipharmaceuticals.com

Debt

Debt-to-Equity Ratio: 1.38
Current Ratio: 3.2
Quick Ratio: 2.17

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CASI Technical Analysis vs Fundamental Analysis

Sell
48
CASI Pharmaceuticals (CASI) is a Sell

Is CASI Pharmaceuticals a Buy or a Sell?